Effective March 11, 2026, UnitedHealthcare clarifies facility expectations and safety details for CAR T–cell therapies in neurologic care: centers offering listed products should be FACT-IEC certified or actively pursuing accreditation. The update highlights rates, timing (commonly 7–12 days), and severity of ICANS and CRS across specific CAR T products and notes the FDA removed the PCNSL limitation for axicabtagene ciloleucel in Feb 2026. Management guidance reiterates supportive care with IL‑6 antagonists (e.g., tocilizumab), corticosteroids, and adjunct agents as used in trials, with ICU-level care required for a subset. Product-specific eligibility, exclusion criteria (including CNS involvement, prior CAR T, active GVHD) and prescribed lymphodepletion regimens are retained to guide risk stratification and institutional preparedness.
March 11, 2026 Revision: Facility Certification and Safety Clarifications
This revision (effective 2026-03-11) clarifies CAR T-cell therapy expectations within UnitedHealthcare's clinical guidance for neurologic and related toxicities associated with IEC (immune effector cell) therapies. The document reiterates that facilities offering CAR T-cell products — including tisagenlecleucel, axicabtagene ciloleucel, brexucabtagene autoleucel, lisocabtagene maraleucel, idecabtagene vicleucel, and ciltacabtagene autoleucel — should be FACT-IEC certified or in the process of obtaining FACT IEC accreditation. The guidance explicitly emphasizes the known toxicities of these therapies, specifically cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), and restates that management is primarily supportive and may include IL-6 antagonists (e.g., tocilizumab) and corticosteroids.
The revision incorporates recent product-specific safety and outcome data summarized from pivotal trials (e.g., rates and timing of CRS and neurologic events) and includes an FDA label update noting removal of the PCNSL limitation for axicabtagene ciloleucel in February 2026. The document consolidates eligibility/medical necessity criteria for multiple CAR T products across indications (B-cell lymphomas, ALL, mantle cell lymphoma, multiple myeloma, follicular lymphoma), preserving therapy-specific lymphodepletion regimens and exclusions such as prior CAR T treatment or active GVHD after allogeneic HSCT where specified.
Neurologic Toxicity (`ICANS`) Incidence, Timing, and Severity by CAR T Product
The policy provides product-specific clinical outcomes and toxicity profiles relevant to neurologic risk across CAR T agents. Reported incidences of neurologic events/ICANS vary by product and trial: brexucabtagene autoleucel reported neurologic events in 60% of patients with 25% grade ≥3 (median onset 9 days; one grade 5 brain herniation), while obecabtagene autoleucel (Aucatzyl) reported ICANS in 22.8% (7.1% grade ≥3; median onset 12 days). Idecabtagene vicleucel (Abecma) reported neurotoxic effects in 18% of patients with high-grade neurotoxicity around 3% in another dataset. Ciltacabtagene autoleucel (Carvykti) reported ICANS in 17% (mostly grade 1–2; median onset 8 days) with all ICANS episodes resolving. Axicabtagene ciloleucel (Yescarta) reported neurologic events in 60% of patients with 21% grade ≥3 (median onset 7 days). Lisocabtagene maraleucel (Breyanzi) reported neurologic events in 30% with 10% grade ≥3. Across studies, median time to neurologic onset commonly fell in the 7–12 day range and durations were typically measured in days to weeks.
Relationship Between `CRS` and Neurologic Events and Reported Management Approaches
The policy documents frequently link the occurrence and management of neurologic events to concurrent or preceding CRS. Several product summaries note overlapping timing (e.g., many neurologic events occur during CRS or shortly after its resolution). Management approaches cited in the source include supportive care, systemic corticosteroids, and adjunctive immunomodulators: tocilizumab (an IL-6 antagonist) is often used for CRS and is reported across trials (e.g., given to 80% with Tecartus, 52% with Aucatzyl, 65% with Yescarta in some cohorts). Anakinra, siltuximab, and additional steroid use appear in select reports (e.g., cilta-cel patients received corticosteroids, tocilizumab and anakinra). ICU admission or vasopressor support were required in subsets of patients for management of CRS and/or neurologic toxicity (examples: 15.7% ICU admission in Aucatzyl program; vasopressors used in Tecartus and Yescarta cohorts).
The document restates that pathophysiology of neurologic toxicity is not fully understood and that treatment is largely supportive with steroids when indicated (citing Neelapu et al., 2018). Outcomes for many ICANS events were favorable in trials where interventions were applied: several agents reported resolution of ICANS in all or most affected patients (e.g., cilta-cel ICANS resolved in all 16 affected patients).
Eligibility, Exclusions, and Lymphodepletion Requirements Relevant to Neurologic Risk
The policy contains detailed, product-specific medical necessity criteria and pre-infusion requirements that have implications for neurologic risk assessment. Across products the document commonly excludes patients with CNS involvement of the underlying malignancy for certain indications (e.g., idecabtagene vicleucel, ciltacabtagene autoleucel list "Member does not have CNS involvement"), while other products have explicit allowances or reported experience with secondary CNS lymphoma in small cohorts (e.g., lisocabtagene maraleucel TRANSCEND included secondary CNS lymphoma patients with observed responses and neurologic event reporting). Additional consistent pre-infusion requirements include the expectation of adequate lymphodepleting chemotherapy per product-specific regimens (examples: fludarabine 30 mg/m2 + cyclophosphamide 300 mg/m2 for many products; cyclophosphamide 500 mg/m2 + fludarabine 30 mg/m2 schedule for axicabtagene ciloleucel and brexucabtagene autoleucel in some indications).
Other recurring eligibility criteria relevant to safety monitoring include exclusion of prior CAR T-cell therapy in most product indications, absence of active GVHD after prior allogeneic HSCT, and age thresholds (typically ≥18 years). The policy preserves these eligibility and lymphodepletion specifics, which influence baseline risk stratification and institutional preparedness for neurologic and other acute toxicities.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.